Platform biomarker company with proprietary EarlyCDT® technology. Developing and commercialising autoantibody (AAb) tests that can enable detection 4 years or more before standard clinical diagnosis, and stratify patients into response to treatment. Two marketed products, EarlyCDT®-Lung launched in 2012 and EarlyCDT®-Liver launched in 2018, and a broad advanced pipeline of early cancer detection tests, incl. prostate, breast and ovarian. Global presence, incl. US (155m US lives covered; 156,000 EarlyCDT®-Lung tests sold since launch) and China. Leading immunogenic library; broad and comprehensive patent portfolio.
Healthcare/Medical Diagnostics & Research
Europe, United Kingdom
Diagnostics, Immuno-Oncology, Oncology
184 Shepherd’s Bush Road
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
European Biotech Investor Day 2019
New York City,
August 1, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by